Pfizer Prices $5B Debt Offering

Pfizer Inc. (NYSE: PFE) today announced the pricing of a debt offering consisting of six tranches of notes:

$300,000,000 aggregate principal amount of floating rate notes due 2023

$1,000,000,000 aggregate principal amount of 3.000% notes due 2021

$1,000,000,000 aggregate principal amount of 3.200% notes due 2023

$1,000,000,000 aggregate principal amount of 3.600% notes due 2028

$700,000,000 aggregate principal amount of 4.100% notes due 2038

$1,000,000,000 aggregate principal amount of 4.200% notes due 2048

Pfizer intends to use the net proceeds for general corporate purposes, including to refinance, redeem or repurchase existing debt and to repay a portion of its outstanding commercial paper.

The closing of the offering is expected to occur on September 7, 2018, subject to satisfaction of customary closing conditions.

Citigroup Global Markets Inc., Credit Suisse Securities (USA) LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated and Morgan Stanley & Co. LLC are acting as joint book-running managers for the offering.

https://www.biospace.com/article/releases/pfizer-prices-5-000-000-000-debt-offering/